149 related articles for article (PubMed ID: 15886470)
21. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
22. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
23. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
24. A simplified premedication schedule for 1-hour paclitaxel administration.
Tsavaris N; Kosmas C; Vadiaka M
J Support Oncol; 2005; 3(1):77-81. PubMed ID: 15724950
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?
Schwartz JR
J Oncol Pharm Pract; 2012 Jun; 18(2):250-6. PubMed ID: 21807762
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer].
Kuroi K; Tanaka C; Bando H; Saji S; Hayashi K; Toi M
Gan To Kagaku Ryoho; 2002 Jan; 29(1):55-60. PubMed ID: 11816478
[TBL] [Abstract][Full Text] [Related]
27. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity reaction to paclitaxel: nursing interventions.
Myers JS
Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
[TBL] [Abstract][Full Text] [Related]
29. [Weekly paclitaxel administration in the adjuvant therapy of primary breast cancer].
Takahashi H; Takahashi M; Taguchi K; Sasaki F; Todo S
Gan To Kagaku Ryoho; 2003 May; 30(5):653-9. PubMed ID: 12795097
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
31. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Kwon JS; Elit L; Finn M; Hirte H; Mazurka J; Moens F; Trim K
Gynecol Oncol; 2002 Mar; 84(3):420-5. PubMed ID: 11855881
[TBL] [Abstract][Full Text] [Related]
32. [A Case of a Suspected Photosensitive Reaction Induced by Weekly Paclitaxel as Neoadjuvant Chemotherapy for Breast Cancer].
Watanabe H; Hoshi I; Nakai Y; Yamasaki K; Abe H
Gan To Kagaku Ryoho; 2015 Aug; 42(8):981-4. PubMed ID: 26321713
[TBL] [Abstract][Full Text] [Related]
33. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Choy H; Yee L; Cole BF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
[TBL] [Abstract][Full Text] [Related]
34. Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.
Hsu CH; Chen MY; Cheng AL
Anticancer Res; 2000; 20(2B):1159-61. PubMed ID: 10810414
[TBL] [Abstract][Full Text] [Related]
35. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
36. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
37. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Hainsworth JD; Greco FA
Cancer; 1994 Aug; 74(4):1377-82. PubMed ID: 7914470
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Dunlea LJ; Rettig AE; Lustberg MB; Phillips GS; Shapiro CL
Support Care Cancer; 2012 Sep; 20(9):1991-7. PubMed ID: 22089428
[TBL] [Abstract][Full Text] [Related]
40. [A patient with paclitaxel hypersensitivity treated with nab-paclitaxel].
Ouchi A; Ouchi A; Asano M; Aono K; Watanabe T; Kato T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):889-91. PubMed ID: 25131878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
